Cancer Research Meeting Calendar  Telomeres
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Supplemental Data
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Meireles, S. I.
Right arrow Articles by Reis, L. F. L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Meireles, S. I.
Right arrow Articles by Reis, L. F. L.
[Cancer Research 64, 1255-1265, February 15, 2004]
© 2004 American Association for Cancer Research


Regular Articles

Molecular Classifiers for Gastric Cancer and Nonmalignant Diseases of the Gastric Mucosa

Sibele I. Meireles1,2, Elier B. Cristo3, Alex F. Carvalho1, Roberto Hirata, Jr.4, Adriane Pelosof2, Luciana I. Gomes1,2, Waleska K. Martins1,2, Maria D. Begnami2, Cláudia Zitron2, André L. Montagnini2, Fernando A. Soares2, E. Jordão Neves3 and Luiz F. L. Reis1,2

1 Ludwig Institute for Cancer Research and2 Hospital do Câncer A.C. Camargo;3 BioInfo and Instituto de Matemática e Estatística da Universidade de São Paulo; and4 SENAC College of Computer Science and Technology, São Paulo, Brazil


    ABSTRACT
 Top
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
 REFERENCES
 
High incidence of gastric cancer-related death is mainly due to diagnosis at an advanced stage in addition to the lack of adequate neoadjuvant therapy. Hence, new tools aimed at early diagnosis would have a positive impact in the outcome of the disease. Using cDNA arrays having 376 genes either identified previously as altered in gastric tumors or known to be altered in human cancer, we determined expression signature of 99 tissue fragments representing normal gastric mucosa, gastritis, intestinal metaplasia, and adenocarcinomas. We first validated the array by identifying molecular markers that are associated with intestinal metaplasia, considered as a transition stage of gastric adenocarcinomas of the intestinal type as well as markers that are associated with diffuse type of gastric adenocarcinomas. Next, we applied Fisher’s linear discriminant analysis in an exhaustive search of trios of genes that could be used to build classifiers for class distinction. Many classifiers could distinguish between normal and tumor samples, whereas, for the distinction of gastritis from tumor and for metaplasia from tumor, fewer classifiers were identified. Statistical validations showed that trios that discriminate between normal and tumor samples are powerful classifiers to distinguish between tumor and nontumor samples. More relevant, it was possible to identify samples of intestinal metaplasia that have expression signature resembling that of an adenocarcinoma and can now be used for follow-up of patients to determine their potential as a prognostic test for malignant transformation.


    INTRODUCTION
 Top
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
 REFERENCES
 
Gastric cancer is still one of the major causes of cancer-related death worldwide, although its incidence is declining during the last decades, as reviewed previously (1) . This high mortality is, at least in part, a consequence of late-stage diagnosis, due to the lack of specific symptoms at early stages of the disease. Moreover, no effective therapeutic strategy is available at advanced stages, and patients often undergo radical gastrectomy leading to high morbidity. Despite the aggressiveness of this treatment, 5-year survival rate in advanced stages is extremely poor, ranging from 5% to 15%. On the contrary, when early diagnosis is successful, there is a higher degree of resectability and better survival rates (2) .

Gastric adenocarcinoma represents >95% of all gastric tumors and, following Lauren’s classification (3) , it can be divided into intestinal and diffuse type, according to tumor histology. These two histological types have a distinct pathology, epidemiology, and etiology. The intestinal type is more frequent and represents the dominant histological type in areas where stomach cancer is epidemic, suggesting an environmental etiology. The pathogenesis of intestinal type adenocarcinoma has been connected to precursor changes such as chronic active gastritis, multifocal atrophic gastritis, intestinal metaplasia, and dysplasia as proposed by Correa and Chen (4) , and with the presence of Helicobacter pylori infection (5) . In contrast, the diffuse type has not been related to precursor lesions and has a higher association with familial occurrence. It is widely accepted that genetic alterations in the CDH1 (e-cadherin) gene play an important role in the oncogenesis of the diffuse-type gastric cancer (6) .

The relationship between intestinal metaplasia and intestinal-type gastric adenocarcinomas has not been fully established. Some individuals with intestinal metaplasia will never develop gastric cancer. The molecular events related to progression from metaplasia to adenocarcinomas remains unknown. Certain molecular alterations have been associated with intestinal metaplasia. For example, mutation in p53 was detected in intestinal metaplasia adjacent to gastric tumors (7) . Overexpression of cyclooxygenase-2 was detected in intestinal metaplasia-associated gastritis (8) , and also detected in gastric cancer and in other tumors like colon cancer (9) . Kang et al. (10) detected promoter hypermethylation in the DNA mismatch repair gene (hMLH1) in intestinal metaplasia, and this epigenetic alteration is related to microsatellite instability. This author also describes hypermethylation of other genes, including p16, DAP-kinase, THBS1, and TIMP-3. Recently, Boussioutas et al. (11) described the expression profile of 124 gastric mucosa representing gastritis, intestinal metaplasia, and adenocarcinomas, and identified a series of genes that are typically expressed in the intestinal type and could be related to tumor progression. Together, these findings demonstrate that some of the molecular events associated with intestinal metaplasia can also be detected in cancer sample and, hence, comparing the molecular alterations between nonmalignant and malignant lesions could lead to the identification of genes involved in gastric carcinogenesis. Moreover, the identification of expression signatures that correlate with adenocarcinomas could be used for follow-up of patients with intestinal metaplasia and assessment of the risk of the premalignant stages becoming malignant.

In this work, we used a cDNA array with 376 genes, including those 141 genes described previously by our group (12) plus other genes known to be generally altered in human cancers. We determined the expression profile in 99 tissue samples representing normal gastric mucosa, as well as gastritis, intestinal metaplasia, and adenocarcinoma of the stomach. Using Fisher’s linear discriminant analysis, we identified a series of molecular classifiers that could distinguish between cancer and noncancer samples. Importantly, we also identify a series of intestinal metaplasias of which the gene expression profile resembles that of adenocarcinoma.


    MATERIALS AND METHODS
 Top
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
 REFERENCES
 
Tissue Samples and RNA Preparations.
Fresh tissue samples were obtained by surgery or by endoscopy at the Gastric Surgery Department and Gastric/Esophagic Endoscopy Department from Hospital do Cancer AC Camargo (São Paulo, Brazil). All of the patients signed an informed consent, and the project was approved by the in-house ethics committee. Tissue samples were either snap frozen in liquid nitrogen or collected in RNAlater, and are represented by 28 gastric adenocarcinomas (18 intestinal type and 10 diffuse type, according to Lauren classification; Ref. 3 ) and 71 nontumor gastric samples (28 normal gastric mucosa, 21 gastritis mucosa, and 22 intestinal metaplasia of the gastric mucosa). Detailed description of samples is presented in Table 1Citation . Samples labeled as "GF" or "GH" were obtained from surgery, and the majority came from patients with gastric adenocarcinomas. Samples labeled as "BIO" were obtained by endoscopic biopsy, and the majority is from patients with only the indicated pathology.


View this table:
[in this window]
[in a new window]

 
Table 1 Description of patients and samples

 
At the time of RNA extraction, histological confirmation of tumor or nontumor status was performed by H&E staining of each individual sample. The frozen sections were also used for tissue dissection to enrich for tumor cells. For tumor specimens, only samples with at least 70% of tumor tissue and free of inflammatory infiltrate were additionally processed. In the case of nontumor samples, only gastric mucosa was used. Total RNA was extracted using TRIzol Reagent (Life Technologies, Inc., Grand Island, NY) following the procedure recommended by the manufacturer.

Production of cDNA Arrays.
We constructed a cDNA array with 376 genes including 141 clones of genes described previously as being altered in gastric cancer (12) and 235 genes known to be altered in human cancers on the basis of available literature (complete gene list is available).5 All of the clones correspond to ORESTES fragments derived from the Fundação de Amparo à Pesquisa do Estado de São Paulo/Ludwig Institute for Cancer Research Human Cancer Genome Project and were sequence verified. Whenever possible, each gene is represented by two clones corresponding to different regions of the complete cDNA and each cDNA clone was printed in triplicates onto nylon membranes (Flexys robot; Genomic Solutions, Ann Arbor, MI) making a total of 2400 spots. Production of the cDNA array, labeling, hybridization, and detection of signals were carried out as described previously (12) . For each tissue sample, 25 µg of total RNA were radioactively labeled with [{alpha}-33P]dCTP (3000 Ci/mmol; Amersham, Piscataway, NJ) and hybridized against a nylon-based cDNA array. Data acquisition was performed with the ArrayVision software (Amersham), using gel files.

Statistical Analysis.
Data analysis was performed using R,6 an open source interpreted computer language for statistical computation and graphics, and tools from the Bioconductor project,7 adapted to our needs. Principal component analysis was performed using TMEV (13) . After image acquisition and quantification (see above), spots with signal lower or equal to background were identified and excluded from the analysis. Next, background-subtracted spot intensities were normalized by global mean normalization procedure (14 , 15) . Replica spots representing the same gene were identified, and average signal intensity was determined.

Next, we searched our data for differentially expressed genes in the four clinical conditions. We used a nonparametric test (Mann-Whitney) to determine the P for each individual gene in each pair-wise comparison. For display purpose, we highlighted genes with P <= 0.0009 in Figs. 1Citation and 3Citation . For all of the pair-wise comparisons (Figs. 1Citation and 3Citation ;Table 2Citation ), genes that are overexpressed in the second entity have the [-log2(P)] preceded by a minus signal. For clustering, we selected the nonredundant set of 6 genes with lowest P for each comparison and used the resulting 18 genes for clustering samples into four groups using the nonsupervised algorithm k-means. Once clusters were obtained, samples were organized hierarchically, based on their correlation distances (16) . For classifiers, we use Fisher’s linear discriminant analysis and made exhausted search of the entire dataset for trios of genes such that data points representing signal intensity for all 3 of the genes for each sample would be separated by a plane in a three-dimensional space. More precisely, for a given group of genes, this linear classification method searches for linear combinations of their expressions with large ratios of between-groups to within-groups sum of squares (16) . This maximal ratio of sum of squares, or its square root, which is denoted here by SVD (singular value decomposition), measures how well separated the two groups are. For the search of trios, the 99 samples dataset was split into two groups, one with 65 samples, used as learning set and a second, independent group, with 34 samples used for validation. Using the learning set of samples (65 samples) we performed an exhaustive search for the best classification trios for each one of the six comparisons of interest among normal, gastritis, metaplasia, and tumor. Trios were ranked according their SVD. In the case of normal versus tumor, where many trios were available, we only considered trios with perfect classification (1044 trios). Next, the best classifiers were tested with the remaining 34 samples with the results presented here.



View larger version (11K):
[in this window]
[in a new window]
[Download PPT slide]
 
Fig. 1. Differentially expressed genes in pair-wise comparison in tissue samples of normal gastric mucosa, gastritis, gastric intestinal metaplasia, and gastric adenocarcinomas. Expression profile from samples representing normal gastric mucosa (N), gastritis (G), intestinal metaplasia (M), and tumor (T) containing 28, 21, 22, and 28 samples, respectively, were analyzed in six pair-wise comparisons, NT, NM, GT, NG, GM, and MT. Genes were distributed according to their [-log2(P)] in each pair-wise comparison. The green and red dots represent genes that showed P < 0.0009 (Mann-Whitney). Green color was used for genes with higher expression in the first entity of the comparison, and red color was used for genes with higher expression in the second entity of the comparison (values preceded by a minus sign).

 


View larger version (17K):
[in this window]
[in a new window]
[Download PPT slide]
 
Fig. 3. Scatter plot representing genes differentially expressed between intestinal and diffuse types of gastric adenocarcinomas. The minus log2 of the Ps for each gene in the NxTi (X axis) and NxTd (Y axis) comparisons were plotted with minus signal indicating overexpression in tumor samples. Genes with P <= 0.0009 (Mann-Whitney) are denoted in green (for only one comparison) or in red (for both comparisons).

 

View this table:
[in this window]
[in a new window]

 
Table 2 Genes differentially expressed in pair-wise comparison of gastric tissue samples

 
Tissue Array.
For the preparation of the stomach tissue microarray, all of the gastrectomy specimens were retrieved from the hospital archives. All of the tissues were fixed in formalin and, from each specimen, H&E-stained slides underwent pathological review to reconfirm diagnosis and selection of blocks. Samples were divided into five groups, histologically normal mucosa (25 cases), chronic gastritis (50 cases), intestinal metaplasia (25 cases), intestinal type adenocarcinoma (75 cases), and diffuse type adenocarcinoma (75 cases). The Lauren type of gastric carcinoma was determined by the following criteria: the intestinal type of gastric adenocarcinoma is histologically characterized by the presence of cohesive cells forming glandular and papillary structure. The diffuse type of gastric carcinoma is characterized histologically by noncohesive cells and the common presence of signet ring cells. Importantly, samples used for RNA extraction represented only a small portion of the samples comprising the tissue microarray.

For the construction of the stomach tissue microarray, new sections were obtained from the representative paraffin blocks, and all of the H&E-stained slides for these cases were reviewed. A slide with representative condition was selected from each case, and an area of one of the studied groups was circled on the slide. The corresponding formalin-fixed, paraffin-embedded blocks were retrieved, and the area corresponding to the selected area on the slide was circled on the block with a felt marker for tissue microarray construction. Using a tissue microarrayer (Beecher Instruments, Silver Spring, MD), the area of interest in the donor paraffin block was cored twice with a 0.6-mm diameter needle and transferred to a recipient paraffin block. Sections of 4 µm were cut from stomach tissue microarray block, deparaffined, dehydrated, and submitted to immunohistochemistry with a polyclonal antibody against metalloproteinase 2 (Oncogene; clone 75–7f7; dilution 1:40). For determining arbitrary units, we gave a score (1, 2, 3, 4) for intensity of staining plus a score (1, 2, 3, 4) for the percentage of positive cells in each tissue spot. Each tissue sample was spotted in duplicate in the slide, and four slides were measured, making a total of eight spots for each tissue sample. All four of the slides were analyzed by two independent pathologists and, for each sample, we sum the two scores (intensity and percentage) for all eight spots gave by each pathologist. Arbitrary units correspond with the average score for each tissue sample (average of 16 determinations for the corresponding eight spots).


    RESULTS
 Top
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
 REFERENCES
 
Identification of Genes Differentially Expressed in Normal, Nonmalignant, and Malignant Diseases.
For the identification of differentially expressed genes in 99 samples representing normal gastric mucosa (n = 28), gastritis (n = 21), intestinal metaplasia (n = 22), and adenocarcinomas of the intestinal type (n = 18) or diffuse type (n = 10), data from all of the hybridizations were background-corrected and normalized as described in "Materials and Methods" leaving a set of 370 genes for analysis. For each gene, we considered the average signal intensity from all of the replica spots. We first compared samples in a pair-wise manner using a nonparametric test (Mann-Whitney) to access significance. In Fig. 1Citation we represent all of the genes and their respective Ps for each pair-wise comparison, indicating in color those with Ps <= 0.0009. Green color was used for genes with higher expression in the first entity of the comparison, and red color was used for genes with higher expression in the second entity of the comparison. As expected, there were more differentially expressed genes when tumor samples were compared with normal, gastritis, or intestinal metaplasia and, conversely, fewer genes with statistically significant differences could be identified when we compare intestinal metaplasia with normal or gastritis. Finally, no statistically significant differences (P <= 0.0009) could be observed in the expression profile when we compared normal versus gastritis. If we consider genes with P < 0.05, a larger number of genes differentially expressed (153 genes) could be identified. In Table 2Citation , we describe the identity of the 42 most differentially expressed genes for each comparison. For convenience, instead of showing the Ps, we present minus the logarithm of the P, which is more directly associated with the significance as it is large for large significance (small Ps), with a minus signal indicating whether the mean expression is higher on the second condition being compared.

We next used a nonsupervised method of clustering to determine whether the 6 genes with lowest Ps for each comparison would be capable of grouping samples based on their expression profiles. Using the {kappa}-means algorithm (16) , samples were grouped in four clusters on the basis of the expression profile of 18 genes that were nonredundant among the 6 genes with lowest Ps for all of the comparisons except normal x gastritis (Fig. 2)Citation . In the first group, the majority of samples representing normal gastric mucosa (green labels) or gastritis (blue labels) were clustered together with only one tumor sample (red labels) and four samples representing metaplasia (brown labels). The second cluster is composed by the majority of samples corresponding to metaplasia plus two normal and three gastritis. The third cluster is composed of a mix of all four of the tissue classes in which a higher expression of the c-Myc oncogene and a lower expression of the CDKN1A gene could be detected. The fourth cluster corresponds with the vast majority of tumor samples, either of the intestinal or the diffuse type plus one gastritis and one metaplasia. Interestingly, when we did principal component analysis along all 99 samples using the expression profile of all 370 genes, the group of 6 samples comprising the third cluster, representing all four of the tissue classes, is detached from the remaining 93 samples, additionally corroborating their unique gene expression profile (figure available elsewhere).5



View larger version (31K):
[in this window]
[in a new window]
[Download PPT slide]
 
Fig. 2. Clustering of the 99 tissue samples according to the expression profile of 18 genes. Using the {kappa}-means algorithm, 99 tissue samples representing normal gastric mucosa (green), gastritis (blue), metaplasia (brown), and adenocarcinomas (red) were grouped into four clusters on the basis of the expression profile of the nonredundant set of 18 genes representing the 6 genes with lowest Ps for each pair-wise comparison. The columns represent genes ordered according to their hierarchical distances. The red color denotes high expression, and the green color denotes low expression as compared with average expression among all 99 of the samples. Within each cluster, samples were ordered on the basis of their correlation distances.

 
Differentially Expressed Genes between Intestinal Type and Diffuse Type Gastric Adenocarcinoma.
As proposed by Correa and Chen (4) , pathogenesis of the intestinal type of gastric adenocarcinoma has been connected to precursor changes in a progressive fashion going from chronic active gastritis, multifocal atrophic gastritis, intestinal metaplasia, and dysplasia. As can be observed in Fig. 2Citation , the fourth cluster has the majority of tumors (25 of 28), with the majority of intestinal type tumors at the bottom branch (14 of 18). Because we could observe this dichotomy in the clustering of two types of gastric adenocarcinomas, we searched for genes differentially among them as compared with normal gastric mucosa (Fig. 3)Citation . Genes with Ps <= 0.0009 (Mann-Whitney Test) are denoted in green (for only one comparison) or in red (for both comparisons). Among the genes with augmented expression in the diffuse type adenocarcinomas we identified matrix metalloproteinase (MMP2), and its overexpression could contribute to the phenotypic characteristics of this tumor. Of notice, expression of the VHL gene was diminished on intestinal type adenocarcinomas.

Tissue Expression of MMP2.
We found MMP2 to be expressed in higher levels in both intestinal and diffuse types of adenocarcinomas (Figs. 4A)Citation . To confirm this observation, we generated a tissue array having 75 samples of diffuse and 75 samples of intestinal types of gastric adenocarcinomas, spotted in duplicates, plus 25 samples of normal gastric mucosa, 50 samples of chronic gastritis, and 25 samples of intestinal metaplasia (total of 500 tissue fragments). In agreement with mRNA levels, both diffuse- and intestinal-type adenocarcinomas showed stronger staining for MMP2 as compared with other entities (Fig. 4, B and C)Citation with a statistically significant difference when we compared normal and all tumor samples (P of 0.036 and 0.034 for Mann-Whitney and t test, respectively). The fact that the majority of the samples used for the stomach tissue microarray were different from those used as source of RNA for gene expression increases the significance of these findings. In the case of diffuse-type adenocarcinomas, we observed that signet ring cells failed to express MMP2 (see panel SRC in Fig. 4BCitation ). A pictorial case stained with a polyclonal antibody against CTNNB1 is available at the provided website.5 This figure clearly demonstrates not only the augmented expression but also changes in cellular localization going from the cell surface in the normal sample to the nucleus in both diffuse and intestinal types of adenocarcinomas (17 , 18) .



View larger version (43K):
[in this window]
[in a new window]
[Download PPT slide]
 
Fig. 4. Overexpression of matrix metalloproteinase 2 in samples of gastric adenocarcinomas. Tissue arrays representing 25 normal gastric mucosa, 50 gastritis, 25 intestinal metaplasia, and 75 samples of each intestinal and diffuse types of adenocarcinomas were stained with anti-matrix metalloproteinase 2 (Oncogene Science). In A we have box plots indicating mRNA expression levels in all four groups of samples (N = normal gastric mucosa; G = gastritis; M = intestinal metaplasia; Ti = intestinal-type adenocarcinoma; and Td = diffuse-type adenocarcinoma) with Ps of 0.0097 for NxTi, 1.5 x 10-5 for NxTd, and 1.9 x 10-5 for NxT. In B we have representative fields of the tissue array stained for matrix metalloproteinase 2 (n = normal gastric mucosa; Ti = intestinal-type adenocarcinoma; Td = diffuse-type adenocarcinoma; SRc = signet ring cells; magnification = x400). In C we represent protein levels in normal and tumor samples (diffuse plus intestinal types) in arbitrary units as defined in "Materials and Methods," as well as the corresponding P (Mann-Whitney).

 
Differentially Expressed Genes during the Evolution to Intestinal Type Gastric Adenocarcinoma.
We next searched for genes that had their expression progressively altered according to the proposed cascade of evolution from normal gastric mucosa, gastritis, and intestinal metaplasia to intestinal type adenocarcinoma, and with Ps <=0.0009 in the extreme comparison i.e., normal versus tumor of the intestinal type (tumors of the diffuse type were excluded from this comparison). The top 7 genes with increased and the top 7 genes with decreased expression are represented in Fig. 5Citation . The 7 selected genes with increased expression pattern were COL1A1, FN1, CTSB, COL1A2, Hs.177781, DAF, and VIM. The 7 selected genes with decreased expression pattern were PRPF8, Hs.327751, VHL, LCK, BAD, VEGFB, and POLR2H.



View larger version (19K):
[in this window]
[in a new window]
[Download PPT slide]
 
Fig. 5. Genes with progressively altered expression according to the cascade of evolution of intestinal-type adenocarcinoma. The top 7 genes with increased (A) or decreased (B) expression pattern according to the cascade of evolution from normal gastric mucosa, gastritis, intestinal metaplasia, and intestinal-type adenocarcinoma are presented. All of the genes have Ps <= 0.0009 (Mann-Whitney) for the NxTi comparison.

 
Construction of Molecular Classifiers.
As the main goal of the present work was the building of molecular classifiers, we next performed an exhaustive search for pairs and trios of genes that could be used for class distinction on the basis of the expression signature of each individual sample. Using the signal intensity of all 370 genes, we applied Fisher Linear Discriminant Analysis (16) and identified all of the possible pairs and trios of genes that could correctly separate tissue samples in each of the six possible comparisons (NxT, NxG, NxM, GxT, GxM, and MxT), allowing none, one, two, or three misclassifications. For the identification of trios we used were a set of 65 samples (learning set). We analyzed 38 samples in NxT comparison, 34 samples in NxG comparison, 29 samples in NxM comparison, 36 samples in GxT comparison, 27 samples in GxM comparison, and 31 samples in MxT comparison. The number of trios found for each comparison is shown in Table 3Citation . We identified 1,044, 17, and 1 trios of genes that could precisely separate all of the normal, gastritis, and intestinal metaplasia from tumor samples, respectively, with perfect distinction of all of the samples. When we accepted one sample misclassified, we found a larger number of trios, 12,278, 512, and 19, for the same comparisons described above, plus 52 and 4 trios that could classify normal and gastritis from intestinal metaplasia, respectively. We could not identify a single trio that could distinguish normal from gastritis even accepting one sample misclassified.


View this table:
[in this window]
[in a new window]

 
Table 3 Identification of classifiers

 
The high number of trios that can distinguish between normal and tumor samples is, in part, because four pair of genes (KIAA0106-COL4A1, CLTC-COL4A1, XBP1-COL4A1, and COL4A1- MCL1) could precisely separate the set of normal and tumor samples used for training.

Next, all of the identified trios represented in Table 3Citation were tested again, in an independent set of 34 samples (validation set), corresponding with an increase of 18 samples in NxT comparison, 15 samples in NxG comparison, 21 samples in NxM comparison, 13 samples in GxT comparison, 16 samples in GxM comparison, and 19 samples in MxT comparison. In Fig. 6Citation we represent the trio with highest SVD (COL4A1, XBP1, and RPL14) and its performance using the training set of samples (Fig. 6A)Citation and the separation of the validation set of samples (Fig. 6BCitation , samples represented by stars) using the same rule defined during training. On the basis of their performance on the learning set of samples, trios were ranked by their SVD score (square root of the ratio of between groups and within groups sum of squares, as explained above). Trios with highest SVD show the least dispersed distribution of samples of a given class and the greater distance between the two classes. We selected the 100 trios with highest SVD score and again determined their performance on the validation set of samples using the rule defined during training (Fig. 6C)Citation or allowed definition of new rules (Fig. 6D)Citation . By comparing Fig. 6, C and DCitation , it can be notice that, when new rules are allowed, classification of samples GF63 improves, but samples BIO124 and GH971 are misclassified by a larger number of trios. The actual numbers for this heatmap is available elsewhere.5



View larger version (34K):
[in this window]
[in a new window]
[Download PPT slide]
 
Fig. 6. Training and validation of classifiers normal and tumor samples. In A we represent the trio (COL4A1, XBP1, and RPL14) with highest SVD and its performance on the training set of normal (green circles) and tumor (red squares) samples. In B we represent the performance of the same trio, for class distinction of the validation set of samples (represented by stars) using the same rule defined during training. In C and D, we represent the performance of the top 100 trios for normal x tumors, based on their singular value decomposition, using either, the same rule defined during training (C) or allowing definition of new rules for each trio during validation (D). The exact numbers represented by the color scale can be obtained at the provided website.5 The color scale represents frequency that a given sample was classified as normal by all classifiers.

 
To estimate the likelihood that good classifiers as the ones we describe were the result of chance, we performed resampling experiments based on a sequential search method for classifier, restricted to the normal x tumor comparison. If N represents the total number of genes (n = 370 in the present situation), the method starts by selecting the best k discriminating genes among the original N genes. Denoting this set of genes by G1, we next search the k best distinct discriminating pairs of genes such that at least one of them belongs to G1. Denoting this set of pairs of genes by G2, we then proceed to search for the k best distinct discriminating trios (denoted by G3) such that at least one of its pairs belong to G2. We finally applied a similar process to get the set G4, the k best distinct discriminating groups of four genes. The motivation of introducing this method is that it can be implemented much faster than the original exhaustive search, and, therefore, is amenable to bootstrap procedures. We applied the method with k = 100 for 1000 bootstrap samples and never found, for any bootstrap search, better results than those corresponding with the real dataset, which strongly suggests that our findings are not due to chance.

Molecular Classification of the 99 Gastric Tissue Samples.
Having identified trios and their respective SVD, we determined the efficiency of these trios to correctly classify all 99 samples. As the number of trios for NxT classification was quite large and very redundant, we selected the top 100 trios for the NxT separation, according to their SVD. For the remaining classification, we used 17, 20, 52, and 4 trios for the GxT, MxT, NxM, and GxM, respectively. The number of genes involved in these trios is 103, 24, 38, 57, and 11, for NxT, GxT, MxT, NxM, and GxM, respectively (the identity of the genes, the structure of the trios, and the identity of misclassified samples can be obtained elsewhere).5 Each of the 99 samples was then classified by all trios of the five comparisons. In Fig. 7Citation , we represent the performance of four trios that can classify NxT, GxT, and MxT. For the NxT classification, we represent the trio with highest SVD with all 54 normal and tumor samples (Fig. 7A)Citation and with all 99 samples (Fig. 7B)Citation . We also represent the best trio that precisely separates all normal and tumor samples (Fig. 7C)Citation , and the same trio with all 99 samples (Fig. 7D)Citation . In Fig. 7, E and FCitation , we represent the trio with highest SVD for GxT and MxT separation with the corresponding samples. The performance of all of the trios against all of the samples is represented in Fig. 8Citation . The spectrum of colors from green to red was used to denote 100% to 0% classification as the first entity of each comparison (for example, in the first line, representing NxT, 100% means all trios classifying the corresponding sample as N and 0% means all trios classifying the corresponding sample as tumor). Thus, a black bar denotes that a sample was classified by 50% of the trios as one of the two entities.



View larger version (37K):
[in this window]
[in a new window]
[Download PPT slide]
 
Fig. 7. Class distinction by trios identified by Fisher’s linear discriminant analysis. The performance of four trios that can classify NxT, GxT, and MxT are represented. For the NxT classification, we represent the trio with highest singular value decomposition with the 54 normal and tumor samples (A) and with all 99 samples (B). We also represent one trio with perfect NxT classification with the 54 normal and tumor samples (C), and with all 99 samples (D). In E and F we represent the trios with best singular value decomposition for GxT and MxT classification with the corresponding samples. Genes are plotted according to their normalized background-corrected log intensities.

 


View larger version (31K):
[in this window]
[in a new window]
[Download PPT slide]
 
Fig. 8. Molecular classification of 99 gastric samples. Each of the 99 samples was classified by the trios according to the five comparisons. The numbers of trios were 100 for NT, 17 for GT, 20 for MT, 52 for NM, and 4 for GM. Color scale represents frequency that a given sample was classified as the first entity of the comparison by each of the trios for that comparison (100% = green; 0% = red).

 
It was expected that samples pertaining to one of the two classes of the classifiers would be colored as green and red because the classifiers were built specifically for them. Indeed, in the first three columns, representing the classifiers having tumor as the second entity produced the vast majority of red bars at the bottom of the figure. Interestingly, there was one normal sample (GF63), two gastritis samples (GF59 and GH880), and three samples of intestinal metaplasia (BIO133, GH828, and BIO136) that were classified as a tumor by >50% of the classifiers for the NxT comparison. Samples GF63, GF59, GH880, BIO133, GH828, and BIO136 were considered as tumor by 93, 66, 98, 88, 99, and 91 trios, respectively. These samples are those that, in Fig. 2Citation , are placed in the third and fourth clusters and, at the principal component analysis, are detached from the remaining samples (figure available).5 Also compatible with the number of genes with significant expression differences observed in Fig. 1Citation , there was a less clear separation of samples in the two columns representing NxM and GxM comparisons but nevertheless, a larger number of red bars can be observed in samples representing intestinal metaplasia.

To determine whether the biological phenomena that were supporting class distinction between tumor and nontumor samples were somehow related, we identified the genes composing the top 45 trios for the NxT distinction plus the genes composing the 17 trios for GxT and the 20 trios for MxT. The number of genes was 50, 24, and 38, respectively, and only 1 gene, CTSB, was at the intersection of the three groups, whereas the sum of the three groups has 100 genes indicating very little redundancy among the genes.

DISCUSSION
During the last 2 years, several groups, including ourselves (12) , published studies focusing on the expression profile of gastric cancer and the identification of differentially expressed genes (19, 20, 21, 22, 23, 24, 25) . Whereas the majority of the published data are based on the comparison between normal and tumor tissues, less information concerning the molecular events that could establish a link between gastric cancer and intestinal metaplasia is available (11) . Likewise, no systematic effort for the construction of molecular classifiers for gastric cancer that could impact on early diagnosis has been reported.

In the present work, we describe the identification of a large set of molecular classifiers that could be used for distinction between normal gastric mucosa and those representing gastritis, intestinal metaplasia, and gastric adenocarcinomas. We have also identified genes of which the gene expression profile can be correlated with the transition stages between normal and intestinal type of adenocarcinomas and genes that are differentially expressed between diffuse and intestinal type of gastric adenocarcinomas.

Before searching for classifiers, we first validated our cDNA array by searching for differentially expressed genes in the various disease states. As expected there were fewer differentially expressed genes when we compared samples representing the nontumor states than comparisons having tumor samples (Fig. 1Citation and Table 2Citation ). As a way to confirm the correlation between our findings and the biology of the process we are dealing with, we determined the pattern of expression of genes that, based on current knowledge, should be altered in our data set. Alterations in the Wnt pathway have been found in a large set of gastric adenocarcinomas, and overexpression of ß-catenin (CTNNB1) in gastric tumors has been described (12 , 17 , 18 , 23 , 25) . We observed over expression of CTNNB1 in this collection of samples in both intestinal and diffuse types of gastric adenocarcinomas (figure available).5 It was reported recently that MMP2 mRNA is elevated in both diffuse and intestinal types of gastric adenocarcinomas (11) , and we have confirmed these observations both at the RNA and at the protein levels (Fig. 4)Citation . Also, KRT20 is typically augmented in intestinal metaplasia and, in agreement with this notion; we found its expression augmented in relation to all other three of the tissue classes (see Table 2Citation ).

The cDNA microarray technology has been largely applied to cancer research (26) , and expression profile is being increasingly used for distinction between physiological and disease states, as well as to distinguish between groups of disease samples of which the expression profile can discriminate between clinically or biologically similar entities (27, 28, 29) . Using a set of 18 nonredundant genes representing the 6 genes with lowest Ps for all six of the pair-wise comparisons, we applied the nonsupervised algorithm k-means to see whether our samples could be grouped accordingly. In Fig. 3Citation , we can observe that the vast majority of samples representing normal and gastritis samples are grouped together, and most of the samples representing intestinal metaplasia and tumors groups in two other clusters. Interestingly, a small cluster with only 6 samples of all four of the entities could be observed and, by the pattern of their expression profile, it is clear that overexpression of MYC and lower expression of CDKN1A is the hallmark of this group of samples. When we did principal component analysis along all 99 samples, this group of 6 samples is detached from the remaining 93 samples (figure available).5 Also, KRT20 was expressed at higher levels in virtually half of the samples from the cluster where the majority of intestinal metaplasias were grouped (see upper branch). There is a controversy on the literature concerning the pattern of expression of KRT20 in intestinal metaplasias of the gastric esophageal junction and its pattern of expression in gastric mucosa (30, 31, 32, 33, 34, 35) . Apparently, KTR20 expression in intestinal metaplasias of the gastric mucosa is also variable. Importantly, we repeated the clustering of samples using self-organizing maps, also a nonsupervised algorithm, and again, samples were grouped with comparable results (data not shown).

The phenotypic and biological differences observed between intestinal- and diffuse-type gastric adenocarcinoma should be a consequence of differences in gene expression. The hallmark of diffuse-type gastric adenocarcinoma is the lack of glandular organization with spreading of tumor cells throughout the parenchyma implying the need for extracellular matrix destruction. In agreement with this notion and in agreement with data presented by Boussioutas et al. (11) , we found MMP2 to be expressed at higher levels in both types of tumor, with diffuse type having even higher mRNA levels than the intestinal type (Fig. 4A)Citation . Again, these data were confirmed by immunohistochemistry in a collection of 150 tumor samples (Fig. 4, B and C)Citation . Interestingly, signet-ring cells, frequently observed in diffuse type of adenocarcinomas, did not express MMP2 (Fig. 4BCitation , signet ring cells or SRc).

To additionally contribute to the understanding of the cascade of events that takes place during the oncogenesis of intestinal type gastric adenocarcinoma, we identified genes of which the expression showed a constant increase or decrease along the cascade from normal to tumor samples with a P <= 0.0009 between the normal and the tumor samples (Fig. 5)Citation . Five of the 7 genes with increased expression toward malignancy have functions related to the extracellular matrix (COL4A1, FN1, CTSB, COL1A2, and VIM). Another gene, DAF, also showed augmented expression from normal to gastritis, metaplasia, and tumor. DAF could be involved in escaping from complement, and its increase expression in gastric cancer was also observed by serial analysis of gene expression analysis (SAGE anatomical viewer8 ). Among the genes of which the expression decreased from normal to tumor samples, we identified the tumor suppressor gene VHL. There are few reports in the literature where the status of VHL gene in gastric cancer was investigated. Leung et al. (36) failed to demonstrate hypermethylation of the promoter region of VHL in 5 gastric cancer cell lines and 26 gastric carcinomas. Diminished expression of the VHL gene, assessed by immune histochemistry was found in 27 of 318 samples of gastric carcinomas (37) . Of notice, there was a diminished expression of BAD, a proapoptotic gene, and such reduced expression could contribute to cell survival. It would be important to see whether there is a correlation between reduced BAD expression and expression of trefoil factor 1, known to antagonizes BAD-induced apoptosis in gastric mucosa (38) . Finally it is likely that reduced expression of LCK just reflects the reduction of infiltrating lymphocytes, because our samples were dissected to exclude inflammatory cells from tumor samples.

Having compared tumor types and identified genes of which the pattern of expression correlates with disease progression we next searched for genes that could be used for the construction of molecular classifiers. As mentioned before, different clustering approaches were successfully used to distinguish between tumor and nontumor samples (24) , morphologically similar samples (29 , 11) , and determine disease outcome (27 , 39) . Whereas a large group of statistical methods is available for such a task, (reviewed in Ref. 40 ), they are often based on the expression of a large set of genes and, necessarily, require data from the two sample groups to identify the set of genes where similarities and differences can be used to define the clusters. To be routinely applied, these requirements could represent potential pitfalls. An alternative would be the implementation of supervised learning procedures where classification could be based on expression signatures rather then comparative expression profile, as proposed earlier (40, 41, 42) . The major advantage would be the possibility of creating a database against which the test sample would be classified, as demonstrated by Ramaswamy et al. (41) . A known group of samples could be used for training and the resulting classifier used for prediction of an unknown sample (class prediction), as demonstrated by Golub et al. (29) . Support vector machine, an example of supervised learning algorithm, was successfully used for class distinction by Shipp et al. (43) and by us (12) . Several other mathematical methods such as Nearest Neighbors Classifiers and Classification Trees (44) could also be applied to search for groups of genes with different expression patterns or sample signature. It appears to us that Fisher’s linear discriminant analysis (16) attains a good compromise between simplicity and performance, making it a good choice for this investigation. Moreover, this approach to identify expression signatures corresponds to the usual approach to identify differentially expressed (single) genes, based on the t-statistics.

Hence, we decided to apply Fisher’s linear discriminant and, by exhausted search among all 370 genes, we identified trios of genes that could be used for class distinction of all four entities in a pair-wise manner (Table 3)Citation . First, it was interesting to observe that the closer along the cascade of disease progression two samples are, the lowest the number of trios. Also, many trios that can distinguish between normal and tumor samples can be explained by the fact that four pairs of genes (KIAA0106-COL4A1, CLTC-COL4A1, XBP1-COL4A1, and COL4A1- MCL1) could precisely separate all 38 of the normal and tumor samples used in the training set of samples. Hence, the list of trios for this comparison is highly redundant for trios composed of these four pairs.

It is noteworthy that, according to our strategy to select cDNA fragments for immobilization in the array, many genes were represented by two or even three cDNA fragments representing distinct regions of the same gene. Thus, it was interesting to determine whether classifiers based on the average signal intensity for all spots of different cDNA fragments corresponding to a given gene would be reproduced when signal intensity of replicas for a single cDNA fragment of that given gene was considered. Indeed, there was a strong correlation between classifiers identified by the two strategies.

All of the trios identified as potential classifiers using the training set of samples were first validated against an independent group of samples, the validation set, comprising 34 new samples using the same classification rule defined during training (Fig. 6C)Citation or by new rules defined during validation (Fig. 6D)Citation . The performances of all of the trios were ranked by their SVD score. Interestingly, the trio with highest SVD, composed of COL4A1, XBP1, and RPL14, misclassified one normal sample (GF63), whereas a trio with lower SVD (TNFRS6, COL4A1, and Hs.325445) correctly classified all 54 of the normal plus tumor samples (Fig. 7, A and CCitation , respectively). With the exception of NxT classification, for which we selected only the top 100 trios with highest SVD, the performance of all of the trios for all five of the comparisons using all 99 samples is represented in Fig. 8Citation . It is noteworthy that, from the 150 genes present in top 45 trios for NxT plus the 17, 20, 52, and 4 trios for the GT, MT, NM, and GM, respectively, a single gene, CTSB, is present in the five groups of classifiers. These data strongly suggest that the biological phenomena that these genes are involved in differ for each comparison.

There is a strong correlation between data from classifiers and from cluster analysis. Samples that are misclassified by the trios are those that were not grouped in the expected cluster in Fig. 2Citation . For the NxT comparison (Fig. 8Citation , first column) there are 6 nontumor samples that were classified as tumor by >50% of the trios; GF 63 (N), GF59 (G), BIO133 (M), and BIO136 (M) were all grouped in the third cluster, whereas GH828 (M) and GH880 (G) fall into the fourth cluster, together with the majority of tumor samples. Together, these observations suggest that the expression profile of the 18 genes used for clustering reflects the structure detected by the signatures identified by the trios. It is important to remember that the 100 trios used for NxT classification are composed of 103 genes. Also, it is clear that the closer the samples are in the cascade of disease progression, the higher the number of misclassified samples, probably reflecting a gradual change in the pattern of gene expression. Nonetheless, there is always a predominant distribution of green and red bars for the samples that represents a given comparison.

The classifiers presented here, based on trios of genes defined by Fisher’s linear discriminant analysis, were able to discriminate tissue samples representing the cascade of events related to gastric adenocarcinomas and should now be validated for class prediction. Importantly, it is now imperative to apply these classifiers to a large set of samples representing intestinal metaplasia to determine the correlation between misclassification of these samples as adenocarcinomas and the frequency they transform into malignant disease. This study will require a large collection of samples and a period of follow-up that cannot be precisely anticipated but is now under way, in a multicentric effort.


    ACKNOWLEDGMENTS
 
We thank Carlos F. Nascimento and Sueli Nonogaki for helping with tissue array, and Dr. Ricardo Brentani for critically reading this manuscript.


    FOOTNOTES
 
Grant support: CEPID-Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP), Grant 98/14335-2. E. J. Neves was partially supported by FAPESP, Grants 99/11962-9 and 99/07390-0, and by Conselho Nacional de Desenvolvimento Cientifico e Tecnológico, Grants 41.96.0923.00 and 521097/2001-0. S. I. Meireles, E. B. Cristo, and L. I. Gomes were supported by fellowships from FAPESP.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Requests for reprints: Luiz F. L. Reis, Rua Prof. Antonio Prudente 109, Sao Paulo, SP 01509-010, Brazil. Phone: 55-11-33883228; Fax: 55-11-32077001; E-mail: lreis{at}ludwig.org.br

5 Internet address: http://array.ludwig.org.br/publications/meirelescancerresearch2003 Back

6 Internet address: http://cran.r-project.org/. Back

7 Internet address: http://www.bioconductor.org. Back

8 Internet address: http://cgap.nci.nih.gov/SAGE/viewer. Back

Received 6/23/03. Revised 12/ 8/03. Accepted 12/10/03.


    REFERENCES
 Top
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
 REFERENCES
 

  1. Stadtlander C. T., Waterbor J. W. Molecular epidemiology, pathogenesis and prevention of gastric cancer. Carcinogenesis (Lond.), 20: 2195-2208, 1999.[Abstract/Free Full Text]
  2. Oliveira F. J., Ferrao H., Furtado E., Batista H., Conceicao L. Early gastric cancer: report of 58 cases. Gastric Cancer, 1: 51-56, 1998.[CrossRef][Medline]
  3. Lauren P. The two histological main types of gastric carcinoma: difuse and so-called intestinal-type carcinoma. Acta Pathol. Microbiol. Scand., 64: 31-49, 1965.[Medline]
  4. Correa P., Chen V. W. Gastric cancer. Cancer Surv., 19–20: 55-76, 1994.
  5. Peek R. M., Jr., Blaser M. J. Helicobacter pylori and gastrointestinal tract adenocarcinomas. Nat. Rev. Cancer, 2: 28-37, 2002.[CrossRef][Medline]
  6. Guilford P., Hopkins J., Harraway J., McLeod M., McLeod N., Harawira P., Taite H., Scoular R., Miller A., Reeve A. E. E-cadherin germline mutations in familial gastric cancer. Nature (Lond.), 392: 402-405, 1998.[CrossRef][Medline]
  7. Shiao Y. H., Rugge M., Correa P., Lehmann H. P., Scheer W. D. p53 alteration in gastric precancerous lesions. Am. J. Pathol., 144: 511-517, 1994.[Abstract]
  8. Sung J. J., Leung W. K., Go M. Y., To K. F., Cheng A. S., Ng E. K., Chan F. K. Cyclooxygenase-2 expression in Helicobacter pylori-associated premalignant and malignant gastric lesions. Am. J. Pathol., 157: 729-735, 2000.[Abstract/Free Full Text]
  9. Dubois R. N. Review article: cyclooxygenase-a target for colon cancer prevention. Aliment. Pharmacol. Ther., 14 (Suppl. 1): 64-67, 2000.
  10. Kang G. H., Shim Y. H., Jung H. Y., Kim W. H., Ro J. Y., Rhyu M. G. CpG island methylation in premalignant stages of gastric carcinoma. Cancer Res., 61: 2847-2851, 2001.[Abstract/Free Full Text]
  11. Boussioutas A., Li H., Liu J., Waring P., Lade S., Holloway A. J., Taupin D., Gorringe K., Haviv I., Desmond P. V., Bowtell D. D. Distinctive patterns of gene expression in premalignant gastric mucosa and gastric cancer. Cancer Res., 63: 2569-2577, 2003.[Abstract/Free Full Text]
  12. Meireles S. I., Carvalho A. F., Hirata R., Montagnini A. L., Martins W. K., Runza F. B., Stolf B. S., Termini L., Neto C. E., Silva R. L., Soares F. A., Neves E. J., Reis L. F. Differentially expressed genes in gastric tumors identified by cDNA array. Cancer Lett., 190: 199-211, 2003.[CrossRef][Medline]
  13. Saeed A. I., Sharov V., White J., Li J., Liang W., Bhagabati N., Braisted J., Klapa M., Currier T., Thiagarajan M., Sturn A., Snuffin M., Rezantsev A., Popov D., Ryltsov A., Kostukovich E., Borisovsky I., Liu Z., Vinsavich A., Trush V., Quackenbush J. TM4: a free, open-source system for microarray data management and analysis. Biotechniques, 34: 374-378, 2003.[Medline]
  14. Yang Y. H., Dudoit S., Luu P., Lin D. M., Peng V., Ngai J., Speed T. P. Normalization for cDNA microarray data: a robust composite method addressing single and multiple slide systematic variation. Nucleic Acids Res., 30: e15 2002.[Abstract/Free Full Text]
  15. Edwards D. Non-linear normalization and background correction in one-channel cDNA microarray studies. Bioinformatics, 19: 825-833, 2003.[Abstract/Free Full Text]
  16. Hastie T., Tibshirani R., Friedman J. . The elements of statistical learning, Springer-Verlag New York 2001.
  17. Grabsch H., Takeno S., Noguchi T., Hommel G., Gabbert H. E., Mueller W. Different patterns of ß-catenin expression in gastric carcinomas: relationship with clinicopathological parameters and prognostic outcome. Histopathology, 39: 141-149, 2001.[CrossRef][Medline]
  18. Woo D. K., Kim H. S., Lee H. S., Kang Y. H., Yang H. K., Kim W. H. Altered expression and mutation of ß-catenin gene in gastric carcinomas and cell lines. Int. J. Cancer, 95: 108-113, 2001.[CrossRef][Medline]
  19. Hasegawa S., Furukawa Y., Li M., Satoh S., Kato T., Watanabe T., Katagiri T., Tsunoda T., Yamaoka Y., Nakamura Y. Genome-wide analysis of gene expression in intestinal-type gastric cancers using a complementary DNA microarray representing 23, 040 genes. Cancer Res., 62: 7012-7017, 2002.[Abstract/Free Full Text]
  20. Inoue H., Matsuyama A., Mimori K., Ueo H., Mori M. Prognostic score of gastric cancer determined by cDNA microarray. Clin. Cancer Res., 8: 3475-3479, 2002.[Abstract/Free Full Text]
  21. Liu L. X., Liu Z. H., Jiang H. C., Qu X., Zhang W. H., Wu L. F., Zhu A. L., Wang X. Q., Wu M. Profiling of differentially expressed genes in human gastric carcinoma by cDNA expression array. World J. Gastroenterol., 8: 580-585, 2002.[Medline]
  22. Lee S., Baek M., Yang H., Bang Y. J., Kim W. H., Ha J. H., Kim D. K., Jeoung D. I. Identification of genes differentially expressed between gastric cancers and normal gastric mucosa with cDNA microarrays. Cancer Lett., 184: 197-206, 2002.[CrossRef][Medline]
  23. El Rifai W., Frierson H. F., Jr., Harper J. C., Powell S. M., Knuutila S. Expression profiling of gastric adenocarcinoma using cDNA array. Int. J. Cancer, 92: 832-838, 2001.[CrossRef][Medline]
  24. Hippo Y., Taniguchi H., Tsutsumi S., Machida N., Chong J. M., Fukayama M., Kodama T., Aburatani H. Global gene expression analysis of gastric cancer by oligonucleotide microarrays. Cancer Res., 62: 233-240, 2002.[Abstract/Free Full Text]
  25. Mori M., Mimori K., Yoshikawa Y., Shibuta K., Utsunomiya T., Sadanaga N., Tanaka F., Matsuyama A., Inoue H., Sugimachi K. Analysis of the gene-expression profile regarding the progression of human gastric carcinoma. Surgery (St. Louis), 131: S39-S47, 2002.
  26. Yeatman T. J. The future of clinical cancer management: one tumor, one chip. Am. Surg., 69: 41-44, 2003.[Medline]
  27. van de Vijver M. J., He Y. D., van’t Veer L. J., Dai H., Hart A. A., Voskuil D. W., Schreiber G. J., Peterse J. L., Roberts C., Marton M. J., Parrish M., Atsma D., Witteveen A., Glas A., Delahaye L., van d. V, Bartelink H., Rodenhuis S., Rutgers E. T., Friend S. H., Bernards R. A gene-expression signature as a predictor of survival in breast cancer. N. Engl. J. Med., 347: 1999-2009, 2002.[Abstract/Free Full Text]
  28. Alizadeh A. A., Eisen M. B., Davis R. E., Ma C., Lossos I. S., Rosenwald A., Boldrick J. C., Sabet H., Tran T., Yu X., Powell J. I., Yang L., Marti G. E., Moore T., Hudson J., Jr., Lu L., Lewis D. B., Tibshirani R., Sherlock G., Chan W. C., Greiner T. C., Weisenburger D. D., Armitage J. O., Warnke R., Staudt L. M. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature (Lond.), 403: 503-511, 2000.[CrossRef][Medline]
  29. Golub T. R., Slonim D. K., Tamayo P., Huard C., Gaasenbeek M., Mesirov J. P., Coller H., Loh M. L., Downing J. R., Caligiuri M. A., Bloomfield C. D., Lander E. S. Molecular classification of cancer: class discovery and class prediction by gene expression monitoring. Science (Wash. DC), 286: 531-537, 1999.[Abstract/Free Full Text]
  30. Couvelard A., Cauvin J. M., Goldfain D., Rotenberg A., Robaszkiewicz M., Flejou J. F. Cytokeratin immunoreactivity of intestinal metaplasia at normal oesophagogastric junction indicates its aetiology. Gut, 49: 761-766, 2001.[Abstract/Free Full Text]
  31. Jovanovic I., Tzardi M., Mouzas I. A., Micev M., Pesko P., Milosavljevic T., Zois M., Sganzos M., Delides G., Kanavaros P. Changing pattern of cytokeratin 7 and 20 expression from normal epithelium to intestinal metaplasia of the gastric mucosa and gastroesophageal junction. Histol. Histopathol., 17: 445-454, 2002.[Medline]
  32. Mohammed I. A., Streutker C. J., Riddell R. H. Utilization of cytokeratins 7 and 20 does not differentiate between Barrett’s esophagus and gastric cardiac intestinal metaplasia. Mod. Pathol., 15: 611-616, 2002.[CrossRef][Medline]
  33. Mouzas I. A., Jovanovic I., Milosavljevic T., Tzardi M., Kanavaros P. Cytokeratin immunoreactivity of intestinal metaplasia. Gut., 51: 894-895, 2002.[Free Full Text]
  34. Odze R. Cytokeratin 7/20 immunostaining: Barrett’s oesophagus or gastric intestinal metaplasia?. Lancet, 359: 1711-1713, 2002.[Medline]
  35. Ormsby A. H., Goldblum J. R., Rice T. W., Richter J. E., Falk G. W., Vaezi M. F., Gramlich T. L. Cytokeratin subsets can reliably distinguish Barrett’s esophagus from intestinal metaplasia of the stomach. Hum. Pathol., 30: 288-294, 1999.[CrossRef][Medline]
  36. Leung W. K., Yu J., Ng E. K., To K. F., Ma P. K., Lee T. L., Go M. Y., Chung S. C., Sung J. J. Concurrent hypermethylation of multiple tumor-related genes in gastric carcinoma and adjacent normal tissues. Cancer (Phila.), 91: 2294-2301, 2001.
  37. Lee H. S., Lee H. K., Kim H. S., Yang H. K., Kim W. H. Tumour suppressor gene expression correlates with gastric cancer prognosis. J. Pathol., 200: 39-46, 2003.[CrossRef][Medline]
  38. Bossenmeyer-Pourie C., Kannan R., Ribieras S., Wendling C., Stoll I., Thim L., Tomasetto C., Rio M. C. The trefoil factor 1 participates in gastrointestinal cell differentiation by delaying G1-S phase transition and reducing apoptosis. J. Cell Biol., 157: 761-770, 2002.[Abstract/Free Full Text]
  39. Beer D. G., Kardia S. L., Huang C. C., Giordano T. J., Levin A. M., Misek D. E., Lin L., Chen G., Gharib T. G., Thomas D. G., Lizyness M. L., Kuick R., Hayasaka S., Taylor J. M., Iannettoni M. D., Orringer M. B., Hanash S. Gene-expression profiles predict survival of patients with lung adenocarcinoma. Nat. Med., 8: 816-824, 2002.[Medline]
  40. Quackenbush J. Computational analysis of microarray data. Nat. Rev. Genet., 2: 418-427, 2001.[CrossRef][Medline]
  41. Ramaswamy S., Tamayo P., Rifkin R., Mukherjee S., Yeang C. H., Angelo M., Ladd C., Reich M., Latulippe E., Mesirov J. P., Poggio T., Gerald W., Loda M., Lander E. S., Golub T. R. Multiclass cancer diagnosis using tumor gene expression signatures. Proc. Natl. Acad. Sci. USA, 98: 15149-15154, 2001.[Abstract/Free Full Text]
  42. Furey T. S., Cristianini N., Duffy N., Bednarski D. W., Schummer M., Haussler D. Support vector machine classification and validation of cancer tissue samples using microarray expression data. Bioinformatics, 16: 906-914, 2000.[Abstract/Free Full Text]
  43. Shipp M. A., Ross K. N., Tamayo P., Weng A. P., Kutok J. L., Aguiar R. C., Gaasenbeek M., Angelo M., Reich M., Pinkus G. S., Ray T. S., Koval M. A., Last K. W., Norton A., Lister T. A., Mesirov J., Neuberg D. S., Lander E. S., Aster J. C., Golub T. R. Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning. Nat. Med., 8: 68-74, 2002.[CrossRef][Medline]
  44. Dudoit S. Comparison of discrimination methods for the classification of tumors using gene expression data. J. Am. Stat. Assoc., 97: 77-87, 2002.[CrossRef]



This article has been cited by other articles:


Home page
Cancer Res.Home page
I.-S. Song, N. S. Oh, H.-T. Kim, G.-H. Ha, S.-Y. Jeong, J.-M. Kim, D.-I. Kim, H.-S. Yoo, C.-H. Kim, and N.-S. Kim
Human ZNF312b Promotes the Progression of Gastric Cancer by Transcriptional Activation of the K-ras Gene
Cancer Res., April 1, 2009; 69(7): 3131 - 3139.
[Abstract] [Full Text] [PDF]


Home page
Mol Biol EvolHome page
Y. Qu and S. Xu
Quantitative Trait Associated Microarray Gene Expression Data Analysis
Mol. Biol. Evol., August 1, 2006; 23(8): 1558 - 1573.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
L. I. Gomes, G. H. Esteves, A. F. Carvalho, E. B. Cristo, R. Hirata Jr., W. K. Martins, S. M. Marques, L. P. Camargo, H. Brentani, A. Pelosof, et al.
Expression Profile of Malignant and Nonmalignant Lesions of Esophagus and Stomach: Differential Activity of Functional Modules Related to Inflammation and Lipid Metabolism
Cancer Res., August 15, 2005; 65(16): 7127 - 7136.
[Abstract] [Full Text] [PDF]


Home page
Cancer Epidemiol. Biomarkers Prev.Home page
S. Y. Chui, T. M. Clay, H. K. Lyerly, and M. A. Morse
The Development of Therapeutic and Preventive Vaccines for Gastric Cancer and Helicobacter pylori
Cancer Epidemiol. Biomarkers Prev., August 1, 2005; 14(8): 1883 - 1889.
[Abstract] [Full Text] [PDF]


This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Supplemental Data
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Meireles, S. I.
Right arrow Articles by Reis, L. F. L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Meireles, S. I.
Right arrow Articles by Reis, L. F. L.


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online